Afatinib: first global approval
RT Dungo, GM Keating - Drugs, 2013 - Springer
Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development
with Boehringer Ingelheim for the once-daily, oral treatment of cancer. Afatinib …
with Boehringer Ingelheim for the once-daily, oral treatment of cancer. Afatinib …
Molecular histology of lung cancer: from targets to treatments
SL Wood, M Pernemalm, PA Crosbie… - Cancer treatment …, 2015 - Elsevier
Lung cancer is the leading cause of cancer-related death worldwide with a 5-year survival
rate of less than 15%, despite significant advances in both diagnostic and therapeutic …
rate of less than 15%, despite significant advances in both diagnostic and therapeutic …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
GA Masters, S Temin, CG Azzoli, G Giaccone… - Journal of Clinical …, 2015 - ascopubs.org
Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …
Osimertinib in EGFR-mutated lung cancer: a review of the existing and emerging clinical data
CS Lee, M Milone, N Seetharamu - OncoTargets and therapy, 2021 - Taylor & Francis
The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has
improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung …
improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung …
[HTML][HTML] Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with …
F Blackhall, DW Kim, B Besse, H Nokihara… - Journal of Thoracic …, 2014 - Elsevier
Introduction The main objective of the current post hoc analysis was to compare patient-
reported outcomes between crizotinib (N= 172) and chemotherapy subgroups (pemetrexed …
reported outcomes between crizotinib (N= 172) and chemotherapy subgroups (pemetrexed …
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
C Rolfo, E Giovannetti, DS Hong, T Bivona… - Cancer treatment …, 2014 - Elsevier
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients
N Paracha, A Abdulla, KS MacGilchrist - Health and quality of life …, 2018 - Springer
Background Health state utility values (HSUVs) are an important input to economic
evaluations and the choice of HSUV can affect the estimate of relative cost-effectiveness …
evaluations and the choice of HSUV can affect the estimate of relative cost-effectiveness …
[HTML][HTML] Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy
K Domvri, P Zarogoulidis, K Darwiche… - Journal of …, 2013 - ncbi.nlm.nih.gov
Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …
Modulation of pathological pain by epidermal growth factor receptor
Chronic pain has been widely recognized as a major public health problem that impacts
multiple aspects of patient quality of life. Unfortunately, chronic pain is often resistant to …
multiple aspects of patient quality of life. Unfortunately, chronic pain is often resistant to …